13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001652044
Total reported value
$99.1B
$99.1B
29 檔
2.0%
During the Q4 2025 filing period, Alphabet Inc. (CIK: 0001652044) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $99.1B across 29 reported positions.
In Q4 2025, Alphabet Inc. adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 8 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASTS | Ast Spacemobile Inc | Stock-Tech | 25.18% | -17.66% | — | |
| 2 | PL | Planet Labs Pbc | Stock-Industrials | 24.42% | -23.35% | — | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 10.33% | -7.41% | -19.07% | |
| 4 | ARM | Arm Holdings Plc-adr | Stock-Tech | 8.31% | -6.69% | — | |
| 5 | FRSH | Freshworks Inc-cl A | Stock-Other | 7.70% | -3.07% | — | |
| 6 | PATH | Uipath Inc - Class A | Stock-Tech | 4.47% | -1.86% | — | |
| 7 | GTLB | Gitlab Inc-cl A | Stock-Tech | 3.96% | -1.39% | — | |
| 8 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 3.55% | -1.66% | — | |
| 9 | DXCM | Dexcom Inc | Stock-Healthcare | 2.67% | — | — | |
| 10 | MAZE | Maze Therapeutics Inc | Stock-Other | 2.23% | -0.99% | -42.44% | |
| 11 | PRME | Prime Medicine Inc | Stock-Other | 2.23% | -1.38% | — | |
| 12 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.37% | -0.61% | — | |
| 13 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.51% | -0.36% | — | |
| 14 | VERA | Vera Therapeutics Inc | Stock-Other | 0.47% | -0.23% | — | |
| 15 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.45% | -0.27% | -49.12% | |
| 16 | SANA | Sana Biotechnology Inc | Stock-Other | 0.44% | -0.19% | — | |
| 17 | LYEL | Lyell Immunopharma Inc | Stock-Other | 0.35% | -0.15% | — | |
| 18 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.35% | -0.18% | — | |
| 19 | FIG | Figma Inc-cl A | Stock-Other | 0.31% | -0.11% | — | |
| 20 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.27% | -0.13% | — | |
| 21 | WGS | Genedx Holdings CORP | Stock-Other | 0.11% | — | — | |
| 22 | EXK | Exact Sciences CORP | Stock-Materials | 0.09% | — | — | |
| 23 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.08% | -0.05% | — | |
| 24 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.05% | -0.02% | — | |
| 25 | HYPR | Hyperfine Inc | Stock-Other | 0.03% | -0.02% | — | |
| 26 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.03% | -0.02% | EXIT | |
| 27 | QNCX | Quince Therapeutics, Inc. | Stock-Other | 0.02% | — | — | |
| 28 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.01% | — | — | |
| 29 | RGEN | Repligen CORP | Stock-Healthcare | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PL | Planet Labs Pbc | +7.2% | — | Unchanged |
| 2 | ASTS | Ast Spacemobile Inc | +7% | — | Unchanged |
| 3 | RVMD | Revolution Medicines Inc | +2.3% | -19.07% | Trim |
| 4 | PATH | Uipath Inc - Class A | +0.6% | — | Unchanged |
| 5 | VERA | Vera Therapeutics Inc | +0.2% | — | Unchanged |
| 6 | RLAY | Relay Therapeutics Inc | +0.2% | — | Unchanged |
| 7 | LYEL | Lyell Immunopharma Inc | +0.2% | — | Unchanged |
| 8 | EXK | Exact Sciences CORP | 0% | — | Unchanged |
| 9 | SANA | Sana Biotechnology Inc | 0% | — | Unchanged |
| 10 | BEAM | Beam Therapeutics Inc | 0% | — | Unchanged |
| 11 | BBOT | Bridgebio Oncology Therapeut | 0% | — | Unchanged |
| 12 | WGS | Genedx Holdings CORP | 0% | — | Unchanged |
| 13 | SPRO | Spero Therapeutics Inc | 0% | — | Unchanged |
| 14 | QNCX | Quince Therapeutics, Inc. | 0% | — | Unchanged |
| 15 | GLUE | Monte Rosa Therapeutics Inc | — | -49.12% | Trim |
| 16 | AUTL | Autolus Therapeutics PLC | — | — | Unchanged |
| 17 | FULC | Fulcrum Therapeutics Inc | — | — | Unchanged |
| 18 | RGEN | Repligen CORP | — | — | Unchanged |
| 19 | HYPR | Hyperfine Inc | 0% | — | Unchanged |
| 20 | TNYA | Tenaya Therapeutics Inc | 0% | — | Unchanged |
| 21 | OSCR | Oscar Health Inc - Class A | -0.1% | — | Unchanged |
| 22 | FIG | Figma Inc-cl A | -0.2% | — | Unchanged |
| 23 | FRSH | Freshworks Inc-cl A | -0.2% | — | Unchanged |
| 24 | DXCM | Dexcom Inc | -0.2% | — | Unchanged |
| 25 | MAZE | Maze Therapeutics Inc | -0.4% | -42.44% | Trim |
| 26 | GTLB | Gitlab Inc-cl A | -1.1% | — | Unchanged |
| 27 | PRME | Prime Medicine Inc | -1.6% | — | Unchanged |
| 28 | TEM | Tempus Ai Inc-cl A | -1.7% | — | Unchanged |
| 29 | ARM | Arm Holdings Plc-adr | -3.2% | — | Unchanged |
| 30 | ✓ | — | EXIT | Sold out | |
| 31 | DNTH | Dianthus Therapeutics Inc | — | EXIT | Sold out |
| 32 | FHTX | Foghorn Therapeutics Inc | — | EXIT | Sold out |
| 33 | TSHA | Taysha Gene Therapies Inc | — | EXIT | Sold out |
| 34 | TCRX | Tscan Therapeutics Inc | — | EXIT | Sold out |
| 35 | BRNS | Barinthus Biotherapeutics Pl | — | EXIT | Sold out |
| 36 | GUTS | Fractyl Health Inc | — | EXIT | Sold out |
| 37 | ALEC | Alector Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Alphabet Inc. reported a total U.S. public equity portfolio value of $99.1B across 29 disclosed positions in Q4 2025.
During Q4 2025, Alphabet Inc.'s top holdings by market value included ASTS (25.2%)、PL (24.4%)、RVMD (10.3%). The largest single position, ASTS, represented 25.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ASTS, PL, RVMD) accounted for 2.0% of total reported equity market value during Q4 2025.
Top Position Liquidated / Trimmed
前期市值: $198.0M
In Q4 2025, Alphabet Inc. made 11 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 3 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.